Drug Profile
AP 768
Alternative Names: AP768Latest Information Update: 31 Mar 2011
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Actimis Pharmaceuticals
- Class Antiasthmatics; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 31 Mar 2011 No development reported - Phase-I for Asthma in USA (unspecified route)